Waters Corporation (WAT) Covered Calls

Waters Corporation is a global leader in specialty measurement, providing analytical technologies, software, and services that improve human health and well-being. By pioneering innovations in liquid chromatography, mass spectrometry, and thermal analysis, the company supports the life, materials, food, and environmental sciences. Waters is dedicated to accelerating pioneering science, enabling customers to solve complex challenges and drive breakthroughs in medicine and diagnostics.

You can sell covered calls on Waters Corporation to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for WAT (prices last updated Tue 10:55 AM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

Waters operates a highly durable, "razor-and-blade" business model where the majority of its revenue is recurring, derived from high-margin consumables (chemistry) and service contracts. Its technology ecosystem centers on Liquid Chromatography (LC) and Mass Spectrometry (MS), which are essential for drug development and quality control in the biopharmaceutical industry. Following the recent acquisition of Becton, Dickinson & Company’s (BD) Biosciences division, the company has expanded significantly into clinical diagnostics and cellular analysis, creating a new powerhouse division for flow cytometry and microbiology.

The company differentiates itself through its deep focus on regulated, high-volume testing environments where precision, data integrity, and compliance are paramount. Its integrated software platform, Empower, is a standard in laboratory informatics, creating high switching costs for its customer base.

Competitive Landscape

Waters competes in a concentrated global market for life sciences tools. It benchmarks its performance against other liquid and optionable industry giants. Key competitors include Thermo Fisher Scientific, the dominant player in broader laboratory services and equipment; Agilent Technologies, a direct rival in chromatography and mass spectrometry systems; and Danaher Corporation, which competes through its high-performance SCIEX subsidiary. Investors monitor these firms for insights into biopharma R&D spending, global healthcare diagnostics demand, and the impact of integration efforts on operating margins.

Market participants track these companies to evaluate the health of the life sciences cycle, the pace of innovation in new modalities like biologics, and the success of supply chain and synergy execution.

Strategic Outlook and Innovation

Waters’ strategic outlook is defined by its focus on expanding into high-growth "new modalities" such as cell and gene therapy, and the successful integration of the BD Biosciences assets. Innovation is prioritized in "walk-up" simplicity—making complex analytical instruments more accessible to non-experts—and cloud-based informatics. By leveraging its increased scale following the BD deal, the firm aims to capture greater market share in clinical and advanced diagnostics.

Future growth is expected to stem from its expanded portfolio in diagnostics, the continued penetration of its premium separation science products in emerging markets, and disciplined realization of cost and revenue synergies. As a provider of essential infrastructure for the global scientific community, Waters remains a core player for investors seeking exposure to the long-term growth of the life sciences sector.

Want more examples? WASH Covered Calls | WAY Covered Calls